Doctors Call for Study of Marijuana

Originally appearing here. The Massachusetts Medical Society, which steadfastly opposed the medical marijuana ballot question approved by voters in November, called on Friday for large-scale research of the drug’s potential medical uses to ensure it is tested in the same rigorous way as prescription drugs. At the same time, the organization representing the state’s doctors said it has dropped a push to change federal regulations and remove marijuana from a list of the most dangerous drugs — a classification that some scientists cite as an obstacle to the research. Dr. Richard Aghababian, the group’s president, sent a letter in October urging the US Drug Enforcement Administration to facilitate research by reclassifying marijuana, removing it from a list of the most dangerous illegal substances for which regulators see “no currently accepted medical use.” The agency responded recently, saying marijuana’s status as a Schedule I drug “does not preclude scientific research” on the plant or its components, as long as the research receives proper approvals. “Given this information, it’s time for medical and scientific communities to develop large-scale clinical trials to determine whether marijuana is safe and effective as a medical intervention,”Aghababian wrote Friday on the society’s website. “Such research should identify all the treatment protocols that would apply to a standard pharmaceutical therapy, including indications, contraindications, dosages, length of therapy, side effects, and more.” But the people trying to do exactly that work say the Schedule I classification does get in their way. Aghababian cites the work of a California research center led by Dr. Igor Grant. With state funding and access to the only federally-sanctioned supply of marijuana, that center has conducted a series of small studies that have found marijuana relieved pain in patients with HIV or other conditions and eased muscle stiffness in people with multiple sclerosis. Grant and colleagues wrote last year in the Open Neurology Journal that marijuana’s Schedule I classification is untenable and inaccurate. The body of evidence showing marijuana may help to control pain and nausea is growing, they wrote, and larger trials are warranted. “The classification of marijuana as a Schedule I drug as well as the continuing controversy as to whether or not cannabis is of medical value are obstacles to medical progress in this area,” the researchers wrote. Rick Doblin of Belmont, executive director of the Multidisciplinary Association for Psychedelic Studies, said the real obstacle to research is not the drug’s classification but limits on access to the federal drug supply — he called it a monopoly by the National Institute of Drug Abuse, aided by the DEA. His association has tried to gain access to the sanctioned drug to study the effects of marijuana in veterans with post-traumatic stress disorder, but the proposal was rejected by federal reviewers who said it was not scientifically sound. The group is trying again. The association has been working for 12 years with a University of Massachusetts professor to try to establish another facility in which to grow marijuana in the controlled setting that research requires. The DEA denied the professor’s application for a facility license in 2009, a decision he is appealing in federal court. The medical society does not plan to respond to the DEA letter, spokesman Rick Gulla said. “The letter satisfies our concern,” Gulla said. “We still must recognize that marijuana has a potential for abuse and is prohibited under federal law.” The Boston Globe provides a detailed account of medical marijuana in both scientific and legal contexts. Despite its Schedule I status, MAPS’ proposed medical marijuana research has received approval from the Food and Drug Administration (FDA). Professor Lyle Craker won a 2009 Drug Enforcement Administration (DEA) Administrative Law Judge hearing and is now suing the DEA for rejecting his application to start a farm to provide marijuana to privately-funded research. MAPS Executive Director Rick Doblin is interviewed, speaking on how the National Institute of Drug Abuse (NIDA) and the DEA are preventing vital research from happening.